Minerva Neurosciences | NERV - Equity Capital And Reserves


Minerva Neurosciences reported $-34.58M in Equity Capital and Reserves for its fiscal quarter ending in September of 2025.





Equity Capital And Reserves Change Date
Acadia Pharmaceuticals USD 917.27M 94.89M Sep/2025
Adma Biologics USD 431.19M 32.87M Sep/2025
ALKERMES USD 1.82B 85.86M Dec/2025
Alterity Therapeutics Limited AUD 22.81M 5.29M Jun/2023
AstraZeneca USD 48.67B 2.78B Dec/2025
BioCryst Pharmaceuticals USD -387.89M 33.7M Sep/2025
Bristol-Myers Squibb USD 18.55B 1.06B Sep/2025
Cipla INR 329.19B 16.3B Sep/2025
Clal Biotechnology ILS 121.41M 4.62M Dec/2023
Compugen USD 43.83M 6.43M Sep/2025
CSL USD 18.66B 2.75B Dec/2025
Eli Lilly USD 26.54B 2.74B Dec/2025
Esperion Therapeutics USD -451.36M 17.85M Sep/2025
GlaxoSmithKline GBP 16.38B 229M Dec/2025
Grifols EUR 6.08B 34.72M Sep/2025
Halozyme Therapeutics USD 48.81M 455.1M Dec/2025
Ionis Pharmaceuticals USD 617.97M 13.76M Sep/2025
J&J USD 78.47B 0 Sep/2025
Merck USD 51.85B 2.79B Sep/2025
Minerva Neurosciences USD -34.58M 2.47M Sep/2025
Neurocrine Biosciences USD 3.25B 249.5M Dec/2025
Novartis USD 44.75B 2.7B Sep/2025
Novavax USD -156.67M 194.3M Sep/2025
Pfizer USD 92.8B 4.11B Sep/2025
Roche Holding CHF 33.8B 758M Dec/2025
Sanofi EUR 71.71B 1.55B Dec/2025
Takeda JPY 7.64T 513.39B Dec/2025
Vanda Pharmaceuticals USD 327.19M 138.81M Dec/2025